12:00 AM
 | 
Apr 13, 2009
 |  BC Week In Review  |  Company News  |  Sales & Marketing

InSite, Nitten Pharmaceutical Co. Ltd. sales and marketing update

Nitten received exclusive rights to commercialize InSite's AzaSite azithromycin to treat ocular bacterial infections in Japan and Taiwan. Nitten will be responsible for...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >